Efficacy of non-intensive therapies approved for relapsed/refractory acute myeloid leukemia: a systematic literature review
| Autor: | T Alexander Russell-Smith, Laura Gurskyte, Bogdan Muresan, Carla M Mamolo, Ana Gezin, Joseph C Cappelleri, Bart Heeg |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Future Oncology. 18:2029-2039 |
| ISSN: | 1744-8301 1479-6694 |
| Popis: | Some patients with acute myeloid leukemia (AML) have no response to initial treatment or have a response that is subsequently lost. Follow-on treatment options after that initial stage are limited, especially for patients who are not able to have intensive therapy, such as chemotherapy, due to age, physical or cognitive function, existing comorbidities or symptoms. This study aimed to review the published literature to identify data associated with treatments that are licensed for use in patients ineligible for intensive therapy who do not maintain a response from their initial therapy. The study found that the drug gilteritinib was an option for the subgroup of AML patients with FLT3-mutated disease with an average life expectancy just under 1 year, while gemtuzumab ozogamicin was an option for a wider group of AML patients with a life expectancy just over 1 year. Between a fifth and a quarter of patients went on to receive a stem-cell transplant after treatment with one of these. With limited options, this patient group needs further attention; however, the availability of the previously mentioned treatments is promising. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|